Celastramycin A
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Celastramycin A is an antibiotic that inhibits the growth of bacteria and mycobacteria and is also a potent innate immune suppressor [1][2].
Celastramycin A is a benzoyl pyrrole-type compound isolated from endophytic bacteria Streptomyces MaB-QuH-8 living in plants of the Celastraceae family. Celastramycin A exhibited high activity against a series of multiresistent bacteria and mycobacteria [1]. Celastramycin A inhibited the growth of Gram-positive bacteria and mycobacteria with minimal inhibitory concentration (MIC) as low as 0.05 μg/ml [1]. In the ex vivo Drosophila culture system, Celastramycin A showed a potent immunosuppressive effect with IC50 value of 0.008 μg/mL. In human umbilical vein endothelial cells (HUVECs), Celastramycin A potently inhibited the production of IL-8 with IC50 value of 0.06 μg/mL. So Celastramycin A could be used as a lead compound for novel immunosuppressive agents [2].
References:
[1]. Pullen C, Schmitz P, Meurer K, et al. New and bioactive compounds from Streptomyces strains residing in the wood of Celastraceae. Planta. 2002 Nov;216(1):162-7.
[2]. Kikuchi H, Sekiya M, Katou Y, et al. Revised structure and synthesis of celastramycin a, a potent innate immune suppressor. Org Lett. 2009 Apr 16;11(8):1693-5.
| Physical Appearance | A crystalline solid |
| Storage | Store at -20°C |
| M.Wt | 390.7 |
| Cas No. | 491600-94-3 |
| Formula | C17H18Cl3NO3 |
| Solubility | ≤20mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide |
| Chemical Name | (3-chloro-5-hexyl-2,6-dihydroxyphenyl)(4,5-dichloro-1H-pyrrol-3-yl)-methanone |
| SDF | Download SDF |
| Canonical SMILES | ClC1=CC(CCCCCC)=C(O)C(C(C2=CC(Cl)=C(Cl)N2)=O)=C1O |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
| 细胞实验 [1]： | |
|
细胞系 |
人脐静脉内皮细胞（HUVEC） |
|
溶解方法 |
在DMSO中的溶解度≤ 20mg/ml。为了获得更高的浓度，可以将离心管在37℃加热10分钟和/或在超声波浴中震荡一段时间。原液可以在-20℃以下储存几个月。 |
|
反应条件 |
0.06 μg/ml |
|
应用 |
在人脐静脉内皮细胞（HUVEC）中，celastramycin A有效抑制IL-8的产生，其IC50为0.06 μg/ mL。因此celastramycin A可以用作新型免疫抑制剂的先导化合物。 |
|
References: [1]. Kikuchi H, Sekiya M, Katou Y, Ueda K, Kabeya T, Kurata S, Oshima Y. Revised structure and synthesis of celastramycin a, a potent innate immune suppressor. Org Lett. 2009 Apr 16;11(8):1693-5. doi: 10.1021/ol9002306. PMID: 19317429. |
|
Quality Control & MSDS
- View current batch:
-
Purity ≥ 97.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
Chemical structure
